Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gross Profit (2022 - 2024)

Historic Gross Profit for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Q4 2024 value amounting to $26.2 million.

  • Amylyx Pharmaceuticals' Gross Profit fell 7763.0% to $26.2 million in Q4 2024 from the same period last year, while for Sep 2025 it was $26.2 million, marking a year-over-year decrease of 8697.54%. This contributed to the annual value of $108.3 million for FY2024, which is 7332.16% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Gross Profit stood at $26.2 million for Q4 2024, which was down 7763.0% from $416000.0 recorded in Q3 2024.
  • Amylyx Pharmaceuticals' 5-year Gross Profit high stood at $117.3 million for Q4 2023, and its period low was $375000.0 during Q3 2022.
  • Moreover, its 3-year median value for Gross Profit was $52.7 million (2023), whereas its average is $54.0 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Gross Profit soared by 2833893.33% in 2023 and then tumbled by 9960.99% in 2024.
  • Amylyx Pharmaceuticals' Gross Profit (Quarter) stood at $23.7 million in 2022, then skyrocketed by 393.98% to $117.3 million in 2023, then plummeted by 77.63% to $26.2 million in 2024.
  • Its Gross Profit was $26.2 million in Q4 2024, compared to $416000.0 in Q3 2024 and $1.0 million in Q2 2024.